GlassScriptPhysician profile
Daniel L Shull
NPI 1508931650
$15,301.42
in general payments reported to CMS, 2019-2025
73 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,223 · 2020: $2,869 · 2021: $2,486 · 2022: $1,870 · 2023: $2,147 · 2024: $1,470 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.31 |
| Education | $122.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,917.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,502.88 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,446.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,177.89 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $883.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $836.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $777.07 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $662.74 | 2021-2025 | |
| Astellas Pharma US INC | $584.54 | 2019-2025 | Veozah |
| Jazz Pharmaceuticals INC. | $492.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $445.55 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.68 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $418.42 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $301.59 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $284.87 | 2019-2025 | Trintellix |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.